- $8.94m
- -$4.16m
- $3.03m
Brief: Neurometrix Reiterates Its Review Of Strategic Alternatives
Brief: NeuroMetrix Announces Steps Taken To Enhance Shareholder Value
Brief: Ephraim Fields Reports 9.3% Stake In Neurometrix, Inc. As Of Feb 23, 2024 - SEC Filing
Brief: RS Fund Reports 14.4% Stake In Neurometrix Inc As Of Feb 13
Brief: Neurometrix Announces Review Of Strategic Options To Promote Growth And Maximize Shareholder Value
Brief: NeuroMetrix Reports Results From Pilot Clinical Trial Of Quell In Post-Acute Covid-19 Syndrome
Brief: NeuroMetrix Announces One-for-Eight Reverse Stock Split
Brief: Neurometrix Collabrates With The National Fibromyalgia Association To Improve The Quality Of Life For People Living With Fibromyalgia
Brief: NeuroMetrix, Inc. reports Q2 revenue USD 1.7 million
Brief: Quell® Demonstrates Encouraging Clinical Trial Results In Chemotherapy Induced Peripheral Neuropathy (Cipn)
Brief: NeuroMetrix Reports Q4 And Full Year 2022 Financial Results
Brief: Neurometrix Announces Strategic Launch Of Quell Fibromyalgia
U.S. autonomous vehicle group picks ex-Senate aide as director
Brief: Neurometrix Reports Q3 2022 Financial Results
Brief: NeuroMetrix Names Jonathan Breck Harmel As National Director Of Sales For Prescription Neurotherapeutics Business
Brief: Neurometrix Reports Q2 2022 Financial Results
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:31 PM
NeuroMetrix surges as FDA authorizes medical device
Brief: NeuroMetrix Reports that Quell Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia